Which chemo causes mds

The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions. Receipt of chemotherapy was associated with a 1. The study cohort included adult patients aged 20 to 84 years whose primary solid tumor diagnosis occurred between and All included patients lived for at least 1 year without having a second primary tumor develop and received initial chemotherapy.

A total of 23 cancer types were included. Second, the NHI database also lacks cancer clinical stage and pathological types, and we cannot adjust these factors to minimize the possible confounding. In additional, it also hampers us using current data to demonstrate the treatment benefit regarding survival rate due to uncontrolled biases.

In conclusion, this population-based nested case—control study found that both RT and CT are related to the subsequent development of MDS. Some cancer sites are more susceptible to developing MDS after cancer treatment. A possible positive interaction between RT and CT may exist. Further research is warranted to validate our findings.

Nevertheless, these results do not dispute the proven benefits of RT and CT in cancer control, which far outweigh the potential risk of MDS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

No additional external funding received for this study. RT increased the risk of MDS for patients with stomach, colorectal, liver, breast, endometrial, prostate, and kidney cancers. CT was more likely to increase the risk of MDS for patients with lung, endometrial, and cervical cancers. The authors have no conflicts of interest to disclose. National Center for Biotechnology Information , U.

Journal List Medicine Baltimore v. Medicine Baltimore. Published online May 1. Author information Article notes Copyright and License information Disclaimer. All rights reserved. This article has been cited by other articles in PMC.

Abstract This study explored which kinds of cancer are related to a higher incidence of subsequent myelodysplastic syndrome MDS after radiotherapy RT and chemotherapy CT.

Open in a separate window. Cancer ; — Surveillance and monitoring of adult cancer survivors. Am J Med ; — Cazzola M, Malcovati L. Myelodysplastic syndromes — coping with ineffective hematopoiesis. N Engl J Med ; — Besa EC. Myelodysplastic syndromes refractory anemia. A perspective of the biologic, clinical, and therapeutic issues.

Med Clin North Am ; 76 — Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int ; — Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis — BMC Cancer ; 11 Cole M, Strair R.

Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review. Am J Med Sci ; — Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica ; 92 — Treatment-related myelodysplastic syndrome following abdominopelvic radiotherapy for endometrial cancer. Gynecol Oncol ; 57 — Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.

J Natl Cancer Inst ; :djt Myelodyeplastic syndrome following therapy for brain tumor — two case reports. Neurol Med Chir Tokyo ; 42 — Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Br J Pharmacol ; — Cheng TM. Taiwan's National Health Insurance system: high value for the dollar. In Okma K. New Jersey: World Scientific, , pp. Graubert T. Therapy-related myelodysplastic syndrome: models and genetics. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol ; 51 — Grossi A, Liumbruno GM. New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support? Blood Transfus ; 6 — Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors.

J Clin Oncol ; 29 — Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epidemiol ; 34 — The only known risk factor over which you have any control is exposure to ionizing radiation or chemicals. If you work with radiation or chemicals, follow all the safety measures in place to protect yourself.

The Stanford Medicine Online Second Opinion program offers you easy access to our world-class doctors. Visit our online second opinion page to learn more. Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials. Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Share on Facebook. Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience. View the changes to our visitor policy » View information for Guest Services ». New to MyHealth? Manage Your Care From Anywhere.